Pfizer Inc. $PFE Stock Position Lifted by Money Concepts Capital Corp

Key Points

• Money Concepts Capital Corp lifted its Pfizer stake 29.9% in Q3 to 248,251 shares (an additional 57,188) valued at about $6.33 million, part of wider institutional buying that leaves institutions owning 68.36% of PFE.
• Recent results and guidance: Pfizer beat EPS estimates ($0.87 vs. $0.79) and set FY2025 guidance of $3.00–$3.15 per share (consensus ~2.95), with Q4/full‑year results due Feb. 3 as a near‑term catalyst.
• Valuation and dividend: PFE trades near $26.43 with a $150.2B market cap and a P/E of ~15.4, and it pays a $0.43 quarterly dividend (6.5% yield) with a 100% payout ratio.

Money Concepts Capital Corp lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 29.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 248,251 shares of the biopharmaceutical company's stock after purchasing an additional 57,188 shares during the quarter. Money Concepts Capital Corp's holdings in Pfizer were worth $6,325,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Fiduciary Alliance LLC lifted its position in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock worth $3,701,000 after buying an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Pfizer in the third quarter worth $3,019,000. Vista Investment Partners LLC raised its holdings in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock worth $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. boosted its position in Pfizer by 76.4% during the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company's stock valued at $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in Pfizer by 11.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company's stock valued at $48,225,000 after purchasing an additional 190,946 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.2%

NYSE:PFE opened at $26.43 on Monday. The company's 50 day moving average is $25.52 and its 200-day moving average is $25.03. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The firm has a market cap of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer's dividend payout ratio is presently 100.00%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PFE shares. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an "equal weight" rating for the company in a research note on Friday, December 12th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a report on Thursday, January 22nd. TD Cowen reiterated a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. HSBC reissued a "buy" rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Finally, UBS Group started coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a "neutral" rating and a $25.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post‑COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi‑year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
• Positive Sentiment: Pfizer struck a non‑exclusive licensing agreement to access Novavax’s Matrix‑M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full‑year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near‑term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near‑term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short‑term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.